Sodium Butyrate | Butyric Acid;NaB;Butanoic acid sodium salt | 正丁酸钠 | Aliphatic Acyl | HDAC

首页 / / / / Sodium Butyrate

丁酸钠 /Sodium Butyrate {[allProObj[0].p_purity_real_show]}

货号：A239433 同义名： 正丁酸钠 / Butyric Acid;NaB

Sodium Butyrate 是一种 HDAC 抑制剂，具有诱导细胞分化和抑制细胞增殖的作用。Sodium Butyrate 可用于癌症、炎症性疾病和代谢性疾病的研究。

Sodium Butyrate 化学结构
CAS号：156-54-7

Sodium Butyrate 3D分子结构
CAS号：156-54-7

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Sodium Butyrate 纯度/质量文件产品仅供科研

货号：A239433 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

组蛋白去乙酰化酶亚型比较

产品名称	HD1 ↓ ↑	HD2 ↓ ↑	HDAC ↓ ↑	HDAC1 ↓ ↑	HDAC10 ↓ ↑	HDAC11 ↓ ↑	HDAC2 ↓ ↑	HDAC3 ↓ ↑	HDAC4 ↓ ↑	HDAC5 ↓ ↑	HDAC6 ↓ ↑	HDAC7 ↓ ↑	HDAC8 ↓ ↑	HDAC9 ↓ ↑	其他靶点	纯度
Givinostat HCl monohydrate	++++ HD1-B, IC50: 7.5 nM HD1-A, IC50: 16 nM	+++ HD2, IC50: 10 nM														99%+
MC1568	++ HD1-B (Maize), IC50: 3.4 μM HD1-A (Maize), IC50: 100 nM															96%
Trichostatin A			++++ HDAC, IC50: ~1.8 nM													99%+
Scriptaid			✔													99%+
Valproic acid sodium			✔												Autophagy	97%
AR-42			+++ HDAC, IC50: 30 nM													99%+
Dacinostat			+++ HDAC, IC50: 32 nM													98+%
CUDC-101			++++ HDAC, IC50: 4.4 nM	++++ HDAC1, IC50: 4.5 nM	+++ HDAC10, IC50: 26.1 nM		+++ HDAC2, IC50: 12.6 nM	++++ HDAC3, IC50: 9.1 nM	+++ HDAC4, IC50: 13.2 nM	+++ HDAC5, IC50: 11.4 nM	++++ HDAC6, IC50: 5.1 nM	+ HDAC7, IC50: 373 nM	++ HDAC8, IC50: 79.8 nM	++ HDAC9, IC50: 67.2 nM	HER2,EGFR	99%+
M344			++ HDAC, IC50: 100 nM													99%+
Splitomicin			+ Sir2p, IC50: 60 μM													95%
Panobinostat			++++ HDAC (MOLT-4 cells), IC50: 5 nM HDAC (Reh cells), IC50: 20 nM													98%
Sodium 4-Phenylbutyrate			✔													98%
Vorinostat			+++ HDAC, IC50: ~10 nM													98%
Curcumin			✔												Nrf2,NF-κB	98%
Belinostat			+++ HDAC, IC50: 27 nM													98%
RG-2833				++ HDAC1, Ki: 32 nM				++ HDAC3, Ki: 5 nM								98%
Valproic acid				+ HDAC1, IC50: 0.4 mM												98%
BG45				+ HDAC1, IC50: 2 μM			+ HDAC2, IC50: 2.2 μM	+ HDAC3, IC50: 289 nM								99%+
Entinostat				+ HDAC1, IC50: 0.51 μM				+ HDAC3, IC50: 1.7 μM								98%
Resminostat				+++ HDAC1, IC50: 42.5 nM				++ HDAC3, IC50: 50.1 nM			++ HDAC6, IC50: 71.8 nM					98+%
Romidepsin				+++ HDAC1, IC50: 36 nM			+++ HDAC2, IC50: 47 nM									99%+
Parthenolide				✔											p53,NF-κB	97% HPLC
Tacedinaline				+ HDAC1, IC50: 0.9 μM			+ HDAC2, IC50: 0.9 μM	+ HDAC3, IC50: 1.2 μM								98%
Mocetinostat				++ HDAC1, IC50: 0.15 μM		+ HDAC11, IC50: 0.59 μM	+ HDAC2, IC50: 0.29 μM	+ HDAC3, IC50: 1.66 μM								98%
WT-161				++++ HDAC1, IC50: 8.35 nM			+++ HDAC2, IC50: 15.4 nM				++++ HDAC6, IC50: 0.4 nM					99%+
Fimepinostat				++++ HDAC1, IC50: 1.7 nM	++++ HDAC10, IC50: 2.8 nM	++++ HDAC11, IC50: 5.4 nM	++++ HDAC2, IC50: 5.0 nM	++++ HDAC3, IC50: 1.8 nM			+++ HDAC6, IC50: 27 nM					99%+
Tucidinostat				++ HDAC1, IC50: 95 nM	++ HDAC10, IC50: 78 nM		++ HDAC2, IC50: 160 nM	++ HDAC3, IC50: 67 nM								99%+
Santacruzamate A							++++ HDAC2, IC50: 119 pM									99%+
(E,E)-RGFP966								++ HDAC3, IC50: 80 nM								99%+
LMK-235									+++ HDAC4, IC50: 11.9 nM	++++ HDAC5, IC50: 4.2 nM						99%+
Tasquinimod									✔							99%+
CAY10603											++++ HDAC6, IC50: 2 pM					98%
Tubastatin A											+++ HDAC6, IC50: 15 nM					98%
Tubacin											++++ HDAC6, IC50: 4 nM					99%+
ACY-738											++++ HDAC6, IC50: 1.7 nM					99%+
Nexturastat A											++++ HDAC6, IC50: 5 nM					99%+
BRD73954											+++ HDAC6, IC50: 36 nM		++ HDAC8, IC50: 120 nM			98%
Tubastatin A HCl											+++ HDAC6, IC50: 15 nM		+ HDAC8, IC50: 854 nM			98%
PCI-34051													+++ HDAC8, IC50: 10 nM			99%+
Ricolinostat				++ HDAC1, IC50: 58 nM			++ HDAC2, IC50: 48 nM	++ HDAC3, IC50: 51 nM			++++ HDAC6, IC50: 4.7 nM		++ HDAC8, IC50: 100 nM			99%+
Droxinostat								+ HDAC3, IC50: 16.9 μM			+ HDAC6, IC50: 2.47 μM		+ HDAC8, IC50: 1.46 μM			99%+
Abexinostat				++++ HDAC1, Ki: 7 nM	+++ HDAC10, IC50: 24 nM		+++ HDAC2, Ki: 19 nM	++++ HDAC3/SMRT, Ki: 8.2 nM			+++ HDAC6, Ki: 17 nM		+ HDAC8, IC50: 280 nM			98%+
Citarinostat				+++ HDAC1, IC50: 35 nM			+++ HDAC2, IC50: 45 nM	+++ HDAC3, IC50: 46 nM			++++ HDAC6, IC50: 2.6 nM		++ HDAC8, IC50: 137 nM			99%+
HPOB				+ HDAC1, IC50: 2.9 μM	+ HDAC10, IC50: 3.0 μM		+ HDAC2, IC50: 4.4 μM	+ HDAC3, IC50: 1.7 μM			++ HDAC6, IC50: 56 nM		+ HDAC8, IC50: 2.8 μM			97%
Quisinostat 2HCl				++++ HDAC1, IC50: 0.11 nM	++++ HDAC10, IC50: 0.46 nM	++++ HDAC11, IC50: 0.37 nM	++++ HDAC2, IC50: 0.33 nM	++++ HDAC3, IC50: 4.86 nM	++++ HDAC4, IC50: 0.64 nM	++++ HDAC5, IC50: 3.69 nM			++++ HDAC8, IC50: 4.26 nM			99+%
Domatinostat				+ HDAC1, IC50: 1.20 μM	+ HDAC10, IC50: 21 μM	+ HDAC11, IC50: 9.7 μM	+ HDAC2, IC50: 1.12 μM	+ HDAC3, IC50: 0.57 μM		+ HDAC5, IC50: 11.3 μM				+ HDAC9, IC50: 50 μM		99%+
TMP269									++ HDAC4, IC50: 157 nM	++ HDAC5, IC50: 97 nM		+++ HDAC7, IC50: 43 nM		+++ HDAC9, IC50: 23 nM		99%+
Pracinostat				++ HDAC1, IC50: 49 nM	+++ HDAC10, IC50: 40 nM	++ HDAC11, IC50: 93 nM	++ HDAC2, IC50: 96 nM	+++ HDAC3, IC50: 43 nM	++ HDAC4, IC50: 56 nM	+++ HDAC5, IC50: 47 nM	+ HDAC6, IC50: 1.008 μM	++ HDAC7, IC50: 137 nM	++ HDAC8, IC50: 140 nM	++ HDAC9, IC50: 70 nM		99%+
TMP195									++ HDAC4, Ki: 59 nM	++ HDAC5, Ki: 60 nM		+++ HDAC7, Ki: 26 nM		+++ HDAC9, Ki: 15 nM		99%+
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Sodium Butyrate 生物活性

描述

Sodium Butyrate is the sodium salt of butyrate with potential antineoplastic activity. Butyrate, a short chain fatty acid, competitively binds to the zinc sites of class I and II histone deacetylases (HDACs). This binding affects hyperacetylation of histones, resulting in a modified DNA conformation, which subsequently leads to the uncoiling or relaxing of chromatin. NaB (sodium butyrate) corrected the HFD(high-fat diet)-induced gut microbiota imbalance in mice^[3]. Sodium butyrate (NaB) increases α-Synuclein mRNA expression, enhances Atg5-mediated autophagy in murine neuroendocrine STC-1 cells. Moreover, the PI3K/Akt/mTOR pathway was significantly inhibited and cell apoptosis was activated by NaB. NaB-stimulated STC-1 cells induced inflammation in SH-SY5Y cells^[4]. NaB prevents excessive ROS through NOX2 (NADPH oxidase 2) suppression and SOD1 (superoxide dismutase 1) upregulation by p21/NRF2 pathway, which is critical for inhibiting BACE1-dependent amyloidogenesis in neuronal cells exposed to high cholesterol environment^[5]. In vivo, SB (Sodium Butyrate) significantly ameliorated the inflammatory response and intestinal epithelium barrier dysfunction in TNBS (2,4,6-trinitrobenzene sulfonic acid)-induced WT mice. In vitro, pre-treatment with SB dramatically inhibited the expression of TNF-α and IL-6 in LPS-induced RAW246.7 macrophages^[6].

Sodium Butyrate 细胞研究

细胞系	浓度	检测类型	检测时间	活动说明	数据源
human H1299 cells		Function assay	7 days	Inhibition of human USP1/UAF1 in human H1299 cells assessed as reduction in colony formation after 7 days, EC50=3 μM	25229643
human JEG3 cells		Function assay		Inhibition of aromatase in human JEG3 cells by scintillation spectrometry, IC50=0.0015 μM	20148564
human K562 cells	1 mM	Proliferation assay		Antiproliferative activity against human K562 cells at 1 mM in presence of guanosine	23937979

Sodium Butyrate 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01862380	Adrenal Hyperplasia, Congenita... 展开 >>l 21-hydroxylase Deficiency 收起 <<	Not Applicable	Unknown	November 2016	France ... 展开 >> Assistance Publique - Hôpitaux de Paris, Bicêtre Hospital Le Kremlin-bicetre, France, 94 275 收起 <<
NCT03401398	Septic Shock	Phase 3	Not yet recruiting	April 30, 2023	-
NCT03110198	Ulcerative Colitis, Unspecifie... 展开 >>d 收起 <<	Phase 4	Recruiting	March 2018	China, Shaanxi ... 展开 >> Xijing Digestive Disease Recruiting Xi'an, Shaanxi, China, 710032 Contact: Jie liang, professor 86-029-84771535 liangjie@fmmu.edu.cn 收起 <<

Sodium Butyrate 参考文献

[1]Huang W, Ren C, et al. Inhibition of store-operated Ca(2+) entry counteracts the apoptosis of nasopharyngeal carcinoma cells induced by sodium butyrate. Oncol Lett. 2017 Feb;13(2):921-929.

[2]Jaworska J, Ziemka-Nalecz M, et al. The potential neuroprotective role of a histone deacetylase inhibitor, sodium butyrate, after neonatal hypoxia-ischemia. J Neuroinflammation. 2017 Feb 10;14(1):34.

[3]Zhou D, Pan Q, Xin FZ, Zhang RN, He CX, Chen GY, Liu C, Chen YW, Fan JG. Sodium butyrate attenuates high-fat diet-induced steatohepatitis in mice by improving gut microbiota and gastrointestinal barrier. World J Gastroenterol. 2017 Jan 7;23(1):60-75

[4]Qiao CM, Sun MF, Jia XB, Shi Y, Zhang BP, Zhou ZL, Zhao LP, Cui C, Shen YQ. Sodium butyrate causes α-synuclein degradation by an Atg5-dependent and PI3K/Akt/mTOR-related autophagy pathway. Exp Cell Res. 2020 Feb 1;387(1):111772

[5]Kim SY, Chae CW, Lee HJ, Jung YH, Choi GE, Kim JS, Lim JR, Lee JE, Cho JH, Park H, Park C, Han HJ. Sodium butyrate inhibits high cholesterol-induced neuronal amyloidogenesis by modulating NRF2 stabilization-mediated ROS levels: involvement of NOX2 and SOD1. Cell Death Dis. 2020 Jun 18;11(6):469

[6]Chen G, Ran X, Li B, Li Y, He D, Huang B, Fu S, Liu J, Wang W. Sodium Butyrate Inhibits Inflammation and Maintains Epithelium Barrier Integrity in a TNBS-induced Inflammatory Bowel Disease Mice Model. EBioMedicine. 2018 Apr;30:317-325

Sodium Butyrate 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

9.08mL

1.82mL

0.91mL

45.42mL

9.08mL

4.54mL

90.84mL

18.17mL

9.08mL

Sodium Butyrate 技术信息

CAS号	156-54-7
分子式	C₄H₇NaO₂
分子量	110.087

别名	正丁酸钠 ;Butyric Acid;NaB;Butanoic acid sodium salt
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Inert atmosphere,Room Temperature

溶解度

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01862380	Adrenal Hyperplasia, Congenita... 展开 >>l 21-hydroxylase Deficiency 收起 <<	Not Applicable	Unknown	November 2016	France ... 展开 >> Assistance Publique - Hôpitaux de Paris, Bicêtre Hospital Le Kremlin-bicetre, France, 94 275 收起 <<
NCT03401398	Septic Shock	Phase 3	Not yet recruiting	April 30, 2023	-
NCT03110198	Ulcerative Colitis, Unspecifie... 展开 >>d 收起 <<	Phase 4	Recruiting	March 2018	China, Shaanxi ... 展开 >> Xijing Digestive Disease Recruiting Xi'an, Shaanxi, China, 710032 Contact: Jie liang, professor 86-029-84771535 liangjie@fmmu.edu.cn 收起 <<
NCT03766997	Granulomatous Mastitis	Phase 4	Not yet recruiting	January 2022	China, Beijing ... 展开 >> Department of Breast Surgery,Peking Union Medical College Hospital Beijing, Beijing, China, 100730 收起 <<
NCT01797562	Allergic Contact Dermatitis	Phase 4	Unknown	December 2015	United States, California ... 展开 >> Rady Children's Hospital Recruiting San Diego, California, United States, 92123 Contact: Ann Funk, RN 858-576-1700 ext 4295 Principal Investigator: Lawrence Eichenfield, MD United States, Colorado Anschutz Health and Wellness Center, University of Colorado Recruiting Aurora, Colorado, United States, 80045 Contact: Teresa Derian, RN 303-724-9155 Principal Investigator: Cory Dunnick, MD United States, Kentucky Dermatology Specialists Recruiting Louisville, Kentucky, United States, 40202 Contact: Maureen Beyel, RN 502-582-7546 Principal Investigator: Joseph Fowler, MD United States, Oregon Oregon Health & Science University Recruiting Portland, Oregon, United States, 97239 Contact: Kristin Morton 503-494-6442 Principal Investigator: Patricia Norris, MD 收起 <<
NCT01518348	Contact Dermatitis	Phase 3	Withdrawn(Study has been updat... 展开 >>ed with new protocol number) 收起 <<	December 2013	United States, Colorado ... 展开 >> Anschutz Health and Wellness Center, University of Colorado Aurora, Colorado, United States, 80045 United States, Kentucky Dermatology Specialists Louisville, Kentucky, United States, 40202 收起 <<
NCT00640614	Contact Dermatitis	Phase 3	Completed	-	United States, Arkansas ... 展开 >> River City Dermatology Little Rock, Arkansas, United States, 72205 United States, Kansas American Dermatology Associates Shawnee, Kansas, United States, 66216 United States, Kentucky Dermatology Specialists PSC Louisville, Kentucky, United States, 40202-1864 United States, New York Winthrop University Hospital Mineola, New York, United States, 11501 Denmark Odense University Hospital Odense C, Denmark, DK-5000 收起 <<
NCT02090504	Alcohol Withdrawal Syndrome ... 展开 >> Alcohol Dependence 收起 <<	Phase 4	Completed	-	Austria ... 展开 >> University of Wien Wien, AT, Austria Italy "G. Fontana" Centre for the Study and Multidisciplinary Treatment of Alcohol Addiction, Department of Clinical Medicine, University of Bologna Bologna, BO, Italy Catholic University of Rome Rome, Rm, Italy, 00168 收起 <<
NCT00672308	Cholera	Phase 2	Completed	-	Bangladesh ... 展开 >> ICDDR,B Dhaka, Bangladesh, 1212 收起 <<
NCT01757379	Short Chain Fatty Acids Bioava... 展开 >>ilability 收起 <<	Not Applicable	Completed	-	Belgium ... 展开 >> KU Leuven/ UZ Leuven Leuven, Vlaams-Brabant, Belgium, 3000 收起 <<
NCT01983046	Obesity Type ... 展开 >>2 Diabetes 收起 <<	Not Applicable	Completed	-	Netherlands ... 展开 >> University Maastricht Maastricht, Limburg, Netherlands, 6229 ER 收起 <<
NCT00843167	Breast Cancer ... 展开 >> Precancerous Condition 收起 <<	Phase 2	Completed	-	United States, Oregon ... 展开 >> Knight Cancer Institute at Oregon Health and Science University Portland, Oregon, United States, 97239-3098 收起 <<
NCT00843167	-		Completed	-	-
NCT00693355	Healthy	Not Applicable	Completed	-	Netherlands ... 展开 >> University of Maastricht Maastricht, Limburg, Netherlands, 6202MD 收起 <<
NCT00640614	-		Completed	-	-
NCT00800930	Shigellosis	Phase 2	Completed	-	Bangladesh ... 展开 >> Dhaka Hospital & Matlab Hospital Dhaka, Bangladesh, 1212 ICDDR,B Dhaka, Bangladesh, 1212 收起 <<
NCT03010865	Schizophrenic Disorder ... 展开 >> Cognitive Impairment 收起 <<	Phase 2 Phase 3	Not yet recruiting	February 2020	China, Shanghai ... 展开 >> Shanghai Mental Health Center Not yet recruiting Shanghai, Shanghai, China, 200030 Contact: Chunbo Li, M.D. 86-21-34773243 chunbo_li@163.com Principal Investigator: Chunbo Li, M.D. 收起 <<
NCT02654405	Schizophrenic Disorders ... 展开 >> Cognitive Function 收起 <<	Phase 2 Phase 3	Withdrawn(Nathan Kline Institu... 展开 >>te (NKI) decided not to accept study grant from Stanley Medical Research Foundation. because of budget considerations.) 收起 <<	May 2016	United States, New York ... 展开 >> Nathan Kline Insitute for Psychiatric Research Orangeburg,, New York, United States, 10962 收起 <<
NCT00696098	Gut Health	Not Applicable	Completed	-	Netherlands ... 展开 >> University of Maastricht Maastricht, Limburg, Netherlands, 6202 MD 收起 <<
NCT02271802	SCFA Metabolism	Not Applicable	Completed	-	Netherlands ... 展开 >> Maastricht University Maastricht, Netherlands, 6229ER 收起 <<

丁酸钠 /Sodium Butyrate {[allProObj[0].p_purity_real_show]}

Sodium Butyrate 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Sodium Butyrate 质控信息

Sodium Butyrate 生物活性

Sodium Butyrate 细胞研究

Sodium Butyrate 临床研究

Sodium Butyrate 参考文献

Sodium Butyrate 实验方案

Sodium Butyrate 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

丁酸钠 /Sodium Butyrate {[allProObj[0].p_purity_real_show]}

Sodium Butyrate 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Sodium Butyrate 质控信息

Sodium Butyrate 生物活性

Sodium Butyrate 细胞研究

Sodium Butyrate 临床研究

Sodium Butyrate 参考文献

Sodium Butyrate 实验方案

Sodium Butyrate 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Sodium Butyrate 纯度/质量文件产品仅供科研